NANOG is a key transcription factor for pluripotency in embryonic stem cells. The analysis of NANOG in human cells is confounded by the presence of multiple and highly similar paralogs. In particular, there are three paralogs encoding full-length proteins, namely, NANOG1, NANOG2 and NANOGP8, and at least eight additional paralogs that do not encode full-length NANOG proteins. Here, we have examined NANOG family expression in human embryonic stem cells (hESCs) and in human cancer cell lines using a multi-NANOG PCR that amplifies the three functional paralogs and most of the non-functional ones. As anticipated, we found that hESCs express large amounts of NANOG1 and, interestingly, they also express NANOG2. In contrast, most human cancer cells tested express NANOGP8 and the non-coding paralogs NANOGP4 and NANOGP5. Notably, in some cancer cell lines, the NANOG protein levels produced by NANOGP8 are comparable to those produced by NANOG1 in pluripotent cells. Finally, we show that NANOGP8 is as active as NANOG1 in the reprogramming of human and murine fibroblasts into induced pluripotent stem cells. These results show that cancer-associated NANOGP8 can contribute to promote de-differentiation and/or cellular plasticity.
INTRODUCTION
NANOG is a homeodomain transcription factor, which together with OCT4 and SOX2, constitute the pluripotency transcriptional core in embryonic stem cells. 1, 2 A major complication in the analysis of NANOG in human cells is the fact that there are 11 reported NANOG paralogs. 3 The founding member of the family, NANOG1, is highly expressed in human embryonic stem cells (hESCs). [4] [5] [6] In addition, NANOG1 is an important component of the 'Thomson' cocktail (OCT4, SOX2, LIN28 and NANOG1) for the reprogramming of human cells into induced pluripotent stem cells (iPSCs). 7 In the case of murine cell reprogramming, mouse Nanog accelerates reprogramming with the 'Yamanaka' cocktail (Oct4, Sox2, Klf4, cMyc, abbreviated here as OSKM) 8 and promotes the transition from pre-iPSCs to iPSCs. 2 Finally, human NANOG1 can replace mouse Nanog in the pre-iPSC to iPSC transition of murine cells, indicating cross-species functional conservation. 9 Recently, NANOG2 was identified in human leukemic cells sharing with NANOG1 a similar intron-exon structure and a highly conserved promoter region. 10 However, it is not known whether NANOG2 is expressed in hESCs. In addition to NANOG1 and NANOG2, there are nine intronless paralogs, named NANOGP2 to NANOGP10, under the control of promoter sequences unrelated to their parental NANOG1 and 2 genes.
3 NANOGP8 is of particular interest because it is the only NANOG intronless paralog with an intact protein coding capacity and, indeed, NANOGP8 protein only differs in two amino acids from NANOG1. 11 Of note, the two amino acids divergent in NANOGP8 relative to NANOG1 are located in important domains for transcriptional regulation, [12] [13] [14] opening the possibility that the function of NANOGP8 could differ from that of NANOG1. Interestingly, NANOGP8 is expressed in many human cancer cell lines, where it has been reported to increase many properties associated with cancer stem cells, including clonogenicity and tumorigenicity. 11, [15] [16] [17] [18] [19] [20] [21] [22] However, there is no direct information on the activity of NANOGP8 in pluripotency assays.
In addition to NANOG, most other reprogramming factors, notably including SOX2, KLF4, OCT4, LIN28 and MYC, are overexpressed in human cancers and, in some cases, have a driving oncogenic role. 23 It is hypothesized that reprogramming factors in cancer contribute to cellular plasticity and this could be a critical oncogenic feature. 23 In this work, we have performed a comprehensive analysis of the expression of NANOG paralogs in human cancer cell lines and have tested the activity of NANOGP8 in reprogramming.
RESULTS

Expression of NANOG paralogs in human cells
To facilitate the analysis of NANOG paralogs in human cancer cell lines, we designed a multi-NANOG reverse transcriptase-PCR strategy based on two forward primers and one reverse primer with the potential to amplify most NANOG paralogs (Figure 1a and Supplementary Figure S1 ). This strategy was designed to obtain a qualitative estimate, rather than a quantitative one, of the expression of NANOG paralogs. NANOGP6 and NANOGP7 were considered too divergent from the rest to be amplifiable by a common set of primers and therefore the multi-NANOG PCR primers were meant to amplify 9 out the 11 NANOG family members. To validate the amplification potential of these primers, we used genomic DNA from human diploid fibroblasts BJ. The resulting PCR band from each of the two reactions was cloned into a plasmid, transformed in bacteria and a total of 201 clones were sequenced ( Figure 1b ). This analysis indicated that the multi-NANOG PCR primers are able to amplify NANOG paralogs P2, P3, P4, P5, P8 and P10. As expected, paralogs P6 and P7 were not amplified. Paralog NANOGP9 was not amplified for reasons that are unclear at the moment. The intron-containing NANOG1 and NANOG2 genes were not amplified from genomic DNA because of the presence of an intron between the primer-anchoring sites. However, their primer-binding sites are identical to those of NANOGP8 (Supplementary Figure S1 ) and, moreover, NANOG1 and NANOG2 were efficiently amplified when using complementary DNA (cDNA; see below). We conclude that the multi-NANOG PCR primers are able to amplify most NANOG paralogs (8 out of 11).
HES2 (hESCs) and NTERA2 (human embryonic teratocarcinoma) cell lines were used as positive controls known to express NANOG1. 4, 5 The multi-NANOG PCR strategy was applied to cDNA from a total of 17 human cancer cell lines (see Materials and methods section for further details; Figure 1b) . As most NANOG paralogs are intronless, we controlled that the cDNA preparations were free of contamination with genomic DNA by performing PCR on the original RNA samples (that is, not treated with reverse transcriptase; Figure 1c ). In agreement with previous studies, 11, [15] [16] [17] [18] [19] most cancer cell lines (14 out of 17) expressed NANOGP8, which is the only intronless paralog with capacity to produce a full-length NANOG protein. All cancer cell lines (17 out 17) expressed NANOGP5 and many (9 out of 17) expressed also NANOGP4, an observation that again is in line with previous reports. 10, 19 The two intron-containing NANOG paralogs, NANOG1 and NANOG2, were the only paralogs detected in HES2 cells, and both were also abundant in NTERA2 cells (Figure 1b) . To our knowledge, this is the first report of NANOG2 expression in human pluripotent cells. Previous investigators have identified NANOG1 expression in glioblastoma cells 11 and in colon cancer cells. 16 In accordance to this, we also detected NANOG1 in some cancer cell lines (Figure 1b) , although quantitative analyses indicated that their levels are extremely low compared with pluripotent cells (see below).
From these analyses, we conclude that the majority of human cancer cells tested express the full-length coding paralog NANOGP8.
Expression of NANOG1 and NANOGP8 in human cells To obtain a quantitative assessment of the levels of NANOG1 and NANOGP8, we designed a set of PCR primers that exclusively amplifies NANOG1 (Figure 2a) , and another one that exclusively amplifies NANOG1 and NANOGP8 (Figure 2b and Supplementary Figure S1 ). Quantitative PCR analyses indicated that NANOG1 levels in human cancer cell lines are residual or undetectable 0 -UTR that is conserved between NANOG1 and NANOGP8. The blue box indicates the coding region. Other symbols are as in Figure 1a . The forward primer binds to the 5 0 -UTR of NANOG1 at a region not conserved in NANOGP8 5 0 -UTR. (b) NANOG1/P8 expression levels in human cancer cell lines. The primers bind both to NANOG1 and NANOGP8 at the positions indicated in the inset. These primers do not amplify the other NANOG paralogs. In parts a and b, mRNA levels were normalized by GAPDH levels and, then, compared with NTERA2 levels (100%). Values correspond to the average ± s.d. (n ¼ 6 PCR replicates). (c) NANOG protein levels in human cancer cell lines. Nuclear extracts were immunoblotted using an antibody against the N-terminal region of NANOG (which only recognizes the proteins derived from NANOG1 and NANOGP8, but not of NANOG2 ). Sizes of protein markers are indicated. NTERA2 was used as a positive control. For NTERA2 cells, the amount of protein loaded was 1 mg; for all the other cell lines, the amount loaded was 10 mg. The cohesin subunit SMC1 was used as a loading control of the nuclear extracts. (d) NANOG knockdown in NTERA2 cells and cancer cell lines. Left, nuclear extracts from NTERA2 cells expressing different shRNA against NANOG, as well as scramble shRNA as a control (SCR), were immunoblotted using an antibody against the N-terminal region of NANOG. Right, nuclear extracts from cell lines 22Rv1, NCI-H727 and MCF-7 expressing shRNAs (pooled shRNAs a-c) against NANOG, as well as scramble shRNA as a control (SCR). Two time-points were collected after shNANOG (shN) infection of cell lines to view decrease in NANOG protein levels (2d and 14d refer to 2 days and 14 days post-infection of shNANOG). In all, 10 mg were loaded for cancer cell lines, and 5 mg were loaded for NTERA2 cells. Nuclear protein SMC1 was used as a loading control. H.E. and L.E. refer respectively to high and low exposure times.
when compared with human pluripotent cells (HES2 and NTERA2; Figure 2a ). In contrast, primers that equally hybridize with NANOG1 and NANOGP8, revealed detectable levels in cancer cell lines (Figure 2b ). These results confirm widespread and abundant expression of NANOGP8 in the human cancer cells analyzed.
Based on the above data, we wondered whether the protein encoded by NANOGP8 was detectable. For this, we performed NANOG immunoblots using nuclear fractions of the previously studied cell lines. In agreement with previous reports, 10, 17, 24 several bands were observed in most cancer cell lines, two bands just below 37 kDa and a single band between 37 kDa and 50 kDa (Figure 2c ). Considering that all the cancer cell lines express NANOGP8, but not NANOG1 (see above Figures 2a and b) , the bands detected by immunoblot must derive from NANOGP8. Of note, the most intense NANOG band in NTERA2 cells corresponds to the upper band and is relatively abundant in cell lines 22Rv1, Du145, LnCAP, NCI-H727 and specially prominent in MCF-7 (Figure 2c ). To confirm that the detected bands correspond to NANOG we performed knockdown of NANOG using three short hairpin RNAs (shRNAs) with perfect matches toward NANOG1 and NANOGP8. In the case of NTERA2 cells, each shRNA potently decreased the upper band and, to a lower extent, also the lower bands (Figure 2d, left) . A similar pattern was observed in cancer cell lines treated with a cocktail of the three shRNAs (Figure 2d , right). These observations confirm that the detected bands correspond to NANOG-derived proteins. At present, however, the molecular bases or significance of the various NANOG protein mobility forms remain speculative. All together, the above mRNA and protein data indicate that most human cancer cell lines studied contain detectable levels of NANOG protein derived from NANOGP8. Importantly, in some cell lines, the levels of NANOGP8 protein are comparable to those of NANOG1 in pluripotent cells.
Reprogramming activity of NANOGP8
Previous studies have concluded that NANOGP8 contributes to the clonogenic and tumorigenic potential of human cancer cells, 11, 17, 18 however, the reprogramming activity of NANOGP8 has not been tested. The NANOG protein encoded by NANOGP8 presents two amino-acid changes relative to the one derived from NANOG1, namely, at positions 16 and 253 (Figure 3a) . These two changes occur in functional protein domains of NANOG. In particular, residue 16 is part of a transcriptional repression domain, 12 whereas residue 253 is within a potent transcriptional activation domain. 13, 14 In addition, NANOG1 presents a coding single-nucleotide polymorphism at codon 82, which can encode for lysine or asparagine, 11 and it is also part of the transcriptional repression domain of NANOG1. 12 Of note, this residue is not polymorphic in NANOGP8, which always presents an asparagine at position 82 (Figure 3a) . Site-directed mutagenesis was used to generate the two polymorphic versions of NANOG1, that is, NANOG1 K82 and NANOG1 N82 . We also generated a construct to express NANOGP8, as well as constructs encoding NANOG1 K82 with each of the two NANOGP8's changes, that is, NANOG1 A16E;K82 and NANOG1 K82;Q253H
. Expression from these vectors was confirmed by transfection of the retroviral vectors into 293T cells and subsequent analysis by quantitative real-time PCR (Supplementary Figures S2A and S2B) .
To explore the functionality of NANOGP8 in pluripotency, we tested the ability of the above-mentioned NANOG expressing constructs to improve the reprogramming efficiency of mouse cells. For this, we used mouse embryonic fibroblasts (MEFs) derived from a reprogrammable transgenic mouse strain developed in our laboratory and carrying a polycistronic OSKM cassette under the control of the tetO element and the reverse transactivator (rtTA) in the Rosa26 locus. Upon doxycycline addition to the medium, these inducible-OSKM MEFs are efficiently reprogrammed. To establish a NANOG-dependent reprogramming assay in murine cells, we took advantage of the following two facts.
On one hand, NANOG accelerates reprogramming 8 and promotes the pre-iPSC to iPSC transition. 2, 9 On the other hand, only bona fide iPSCs are able to grow in the presence of mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) and glycogen synthase kinase (GSK) inhibitors (abbreviated as 2i), whereas 2i medium blocks the proliferation of pre-iPSCs. 25, 26 To identify the conditions at which reprogramming is more dependent on NANOG, inducible-OSKM MEFs were transduced with control (EV) or human NANOG1 K82 and were subsequently treated with doxycycline (day 0). At different time points (day 3, 5, 7 or never), medium was supplemented with 2i and the final number of alkaline phosphatase-positive (AP þ ) colonies was scored at day 14. Transduction of NANOG1 K82 greatly increased the reprogramming efficiency and this was most apparent when adding 2i from day 3 (Figure 3b ). In particular, addition of 2i at day 3 almost completely prevented the emergence of colonies in the absence of NANOG1 K82 . In contrast, the presence of NANOG1 K82 allowed the formation of colonies in 2i medium confirming its ability to accelerate the emergence of fully reprogrammed iPSCs (Figure 3b) .
Having set up a NANOG-dependent reprogramming assay, . We confirmed similar retroviral expression levels in MEFs after infection (Supplementary Figure S3A) . Of note, retroviral expression of mouse or human NANOG did not activate expression of the endogenous mouse Nanog gene (Supplementary Figure S3B) . As mentioned above, we added 2i at day 3 and we scored AP þ colonies at day 14. The two NANOG1 polymorphic variants, NANOG1 K82 and NANOG1
N82
, and NANOGP8 showed equivalent reprogramming activity (Figures 3c and d) . In agreement with this, the two NANOG1 point mutants, NANOG1 A16E;K82 and NANOG1
K82;Q253H
, also showed similar reprogramming activity compared with the wild-type NANOG1 variants. Finally, mouse and human NANOG had a comparable reprogramming activity, extending the previous reported functional conservation of mouse or human NANOG in the pre-iPSC to iPSC transition. 9 We wanted to confirm the above data in the reprogramming of human cells. For this, we used human primary foreskin fibroblasts and the three factor cocktail OCT4, SOX2 and KLF4 (OSK). Cells were retrovirally infected simultaneously with OSK retroviruses together with retroviruses carrying empty vector (EV), or the abovedescribed NANOG constructs. Expression of NANOG variants was confirmed 48 h post-infection ( Supplementary Figures S4A and S4B ) and it did not activate expression of the endogenous NANOG1 gene (Supplementary Figure S4C) . After 28 days, human iPSC colonies were clearly visible and had the standard morphology (Supplementary Figure S5) . Plates were stained with AP and the number of AP þ colonies was scored (Figures 3e and f) . Interestingly, the two polymorphic variants of NANOG1 and NANOGP8 increased reprogramming efficiency to a similar extent and, accordingly, the two NANOG1 point mutants also had a similar effect. Together, these results show that NANOGP8 possesses pluripotency capacity comparable to NANOG1.
DISCUSSION
The NANOG gene family is highly complex in humans, but only three of its members have the capacity to produce full-length proteins, namely NANOG1, NANOG2 and NANOGP8. NANOG1 is highly expressed in pluripotent cells, where it is known to have a critical role and is one of the master regulators of pluripotency.
1,4-6 NANOG2 was found expressed in human leukemic cells, it is located very close to NANOG1 and shares a similar intron-exon structure, suggesting a duplication event. 10 Although our current work is focused on NANOGP8, it is worth Reprogramming activity of NANOGP8 AR Palla et al mentioning that we present evidence indicating that NANOG2 is expressed in hESCs at significant levels. NANOGP8 is expressed in many cancer cell lines where it contributes oncogenic features, including cancer stem cell properties, proliferation, clonogenicity and tumorigenicity. 11, [15] [16] [17] [18] [19] [20] [21] [22] Eventhough the protein encoded by NANOGP8 only differs in two amino acids relative to NANOG1, these two amino acids are located in important domains for transcriptional regulation, [12] [13] [14] opening the possibility that NANOGP8 function could differ from NANOG1. However, there is no evidence for pluripotency activity associated to NANOGP8. In the present work, we make two contributions regarding the relevance of NANOGP8. First, we show that NANOGP8 is widely expressed in cancer cell lines giving rise to full-legth protein products. Previous reports have found a complex pattern of NANOG electrophoretic mobility, 10, 17, 24 although the molecular bases are still unclear. A number of potential mechanisms could account for the different NANOG mobilities, among them phosphorylation, 27 ubiquitylation 27,28 and caspase-mediated cleavage. 29 Importantly, the levels of the upper NANOGP8 band (between 37 kDa and point mutants A16E and Q253H, or NANOGP8. AP þ colonies were scored at day 28. Three replicates were performed and the number of colonies was normalized to the number of colonies appearing in fibroblasts transduced with OSK and NANOG1 K82 . Values correspond to the average ± s.d. The reprogramming efficiency of all the NANOG variants was significantly increased compared with the EV control (Student's t-test Po0.05). The reprogramming efficiencies of the indicated NANOG constructs were not significantly different among themselves. 50 kDa) in some cancer cells are comparable to the levels of NANOG1 in pluripotent cells. Second, we provide direct evidence for the reprogramming activity of NANOGP8. In particular, we have performed two assays, using human and mouse fibroblasts, and in both assays NANOGP8 improved reprogramming efficiency to the same extent as NANOG1. On a marginal note, we also demonstrate that the two polymorphic variants of NANOG1 are equally active in reprogramming.
In addition to NANOG, most other reprogramming factors, notably including SOX2, KLF4, OCT4, LIN28 and MYC, are overexpressed in human cancers and, in some cases, have a driving oncogenic role. 23 It is hypothesized that reprogramming factors in cancer contribute to cellular plasticity and this could be a critical oncogenic feature. 23 Our data demonstrate that NANOGP8 is also a reprogramming factor and, therefore, its widespread expression in cancer cells may contribute to the tumorigenic phenotype by promoting undifferentiated or plastic cellular states, thus fueling cancer growth.
MATERIALS AND METHODS
Cell lines
Cell lines HeLa (cervical cancer), HepG2 (liver cancer), NTERA2 (teratocarcinoma), U20S (osteosarcoma), SAOS2 (osteosarcoma), HCT116 (colon carcinoma), T24 (urinary bladder carcinoma), Hs895T (melanoma), A549 (lung adenocarcinoma), EJ138 (urinary bladder carcinoma) and IMR90 and BJ (normal fibroblasts) were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; HyClone, Logan, UT, USA) and antibiotic-antimycotic solution (Gibco). Cell lines MCF-7 (breast cancer), MDA-MB-231 (breast cancer), NCI-H69 (lung adenocarcinoma), NCI-H727 (lung adenocarcinoma), 22Rv1 (prostate cancer), PC3 (prostate cancer), Du145 (prostate cancer) and LnCAP (prostate cancer) were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS (Hyclone) and antibiotic-antimycotic solution (Gibco). hESCs HES2 (NIH code ES02) were grown in DMEM/F12 supplemented with serum replacement (knockout serum replacement (KSR) 20%, Invitrogen), non-essential amino acids (Lonza, Basel, Switzerland), bmercaptoethanol (Gibco), MEF-conditioned medium (5%) and basic fibroblast growth factor (20 ng/ml, #233-FB, R&D Systems, Minneapolis, MN, USA). 30 For the reprogramming assays, we used mouse embryo fibroblasts containing a doxycycline-inducible cassette expressing the four Yamanaka factors or primary human foreskin fibroblasts (generously provided by Maria S Soengas, CNIO).
Quantitative real-time PCR and cloning Total RNA was obtained using RNeasy Mini Kit (Qiagen, Valencia, CA, USA) following the manufacturer's instructions. Samples were treated with DNase I (Qiagen) before reverse transcription. Total RNA (5 mg) preparations were treated with 'Ready-to-go you-prime first-strand beads' (GE Healthcare, Little Chalfont, UK) to generate cDNA according to the manufacturer's protocol. Control reactions without reverse transcriptase were carried out to exclude DNA contaminations. Quantitative real-time PCR was performed using DNA Master SYBR Green I mix (Applied Biosystems, Foster City, CA, USA) in an ABI PRISM 7700 thermocycler (Applied Biosystems).
PCR primers were as follows:
multi-NANOG PCR:
0 -GTTGCTCTGCATTGGAAGG -3 0 . These primers were selected to amplify all NANOG paralogs except NANOGP6 and NANOGP7, which were considered too divergent from the rest. The primers were chosen to amplify a repertoire of NANOG paralogs as wide as possible, based on multiple alignment analyses and under Tm and specificity considerations.
Two separate multi-NANOG PCR reactions were performed for each cDNA sample: primers F1 and R; or primers F2 and R. The resulting PCR products were gel purified and then ligated into pGEM-T vector (Promega, Fitchburg, WI, USA), transformed into DHa5 Escherichia coli, and individual clones were sequenced.
NANOG1-specific PCR: endogenous-hNANOG1-F, 5 0 -TTCATTATAAATCTAGAGACTCCAGGA-3 0 ; endogenous-hNANOG1-R, 5
0 -CTTTGGGACTGGTGGAAGAATC-3 0 ;
NANOG1/P8-specific PCR: totalNANOG1/P8-F, 5 0 -GCAGAGAAGAGTGTCG-3 0 ; totalNANOG1/P8-R, 5
0 -AGCTGGGTGGAAGAGAACACAG-3 0 ; Other PCR primers were as follows:
Protein analysis
Nuclear protein extracts were prepared using the Nuclear/Cytosol Fractionation kit (K266-100, BioVision, San Francisco, CA, USA) following protocols provided by the manufacturer. For western blot analysis, protein extracts were resolved using NuPAGE 4-12% gradient Bis-Tris gels, transferred to nitrocellulose and hybridized using antibodies against N-terminal-NANOG (1:500, #4903, Cell Signaling Technology, Beverly, MA, USA) and SMC1 (1:1000; A300-055A, Bethyl Laboratories, Montgomery, TX, USA).
NANOG silencing assays
Lentiviruses containing pLKO.1-scramble shRNA (SCR), and pLKO.1-NANOG-shRNA vectors (shRNA-a: TRCN000004885, shRNA-b: TRCN000004886 and shRNA-c: TRCN000004887) obtained from Open Biosystems (Thermo Scientific, Open Biosystems, Huntsville, AL, USA) were produced in 293T cells using the lentivirus packaging plasmids pLP1, pLP2 and pLP/VSVG (Invitrogen), by co-transfecting all plasmids using Fugene HD transfection reagent (Promega) according to the manufacturer's protocol. Cells were plated the day before infection, and supernatants were collected 48 h from 293T cells after transfection. Cell lines MCF7, NCI-H727 and 22Rv1 were infected concomitantly with all three lentiviruses that target NANOG to obtain a synergic silencing effect. Transduced cells were selected with puromycin.
Site-directed mutagenesis of NANOG
The plasmid pMXs-NANOG was obtained from Addgene (Addgene plasmid #18115, Addgene, Cambridge, MA, USA). 31 To obtain the different NANOG variants, site-directed mutagenesis was performed using the QuikChange Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA, USA) following protocols provided by the manufacturer. Mutations were confirmed by Sanger sequencing of the entire NANOG1 open reading frame.
Reprogramming of murine cells
MEFs were obtained from an inducible reprogrammable mouse generated in our laboratory that contains a polycistronic cassette with transcription factors OSKM under the control of the tetO element (tetO-OSKM), 32 as well as, the reverse tetracycline transactivator in the Rosa26 locus (Rosa26::rtTA). 33 Passage 1 MEFs grown in DMEM/10% FBS were plated 1-day before infection (2 Â 10 5 cells per well in six-well gelatin-coated plates). MEFs were infected with NANOG expressing constructs pMXsmNanog (Addgene plasmid #13354), 34 pMXs-NANOG1 K82 (Addgene plasmid #18115), 31 site-directed mutated pMXs-NANOG1 K82 (as described in the main text), pMXs-NANOGP8 (generated from pMXs-NANOG1 K82 by triple site-directed mutagenesis) or with pMXs-empty (produced by excising NANOG1 by EcoRI restriction and re-ligation). At 48 h after the first round of infection, medium was changed to iPSC medium (DMEM high glucose supplemented with serum replacement (KSR, 15%, Invitrogen), leukemia inhibitory factor (LIF) (1000 U/ml), non-essential amino acids, glutamax and b-mercaptoethanol), plus doxycycline (1 mg/ml) to activate expression of OSKM. Three days after doxycycline addition (or when indicated), we supplemented the medium with GSK inhibitor CHIR99021 (1 mM) and with MEK inhibitor PD0325901 (1 mM; both from Axon Medchem, Groningen, The Netherlands). Medium was changed every 36 h, always in the presence of doxycycline and the two inhibitors. Colonies were scored at day 14.
Reprogramming of human cells
Reprogramming of primary human foreskin fibroblasts was done as previously described. 35 Retroviral supernatants were produced in HEK-293T cells grown in DMEM supplemented with 10% FBS (DMEM/10% FBS; 5 Â 10 6 cells per 100 mm diameter dish) transfected with the ectopic packaging plasmid pCL-Ampho (4 mg) and each of the following retroviral constructs (4 mg): pMXs-KLF4 (Addgene plasmid # 17219), pMXs-SOX2 (Addgene plasmid #17218), pMXs-OCT4 (Addgene plasmid #17217) 35 and the NANOG expressing constructs described above (see 'Reprogramming of murine cells' section). Transfections were performed using Fugene HD transfection reagent (Promega) according to the manufacturer's protocol. Two days later, retroviral supernatants were collected serially during the subsequent 48 h, at 12-h intervals, each time adding fresh medium to the cells (10 ml). Primary fibroblasts grown in DMEM/10% FBS had been seeded the previous day of infection (2 Â 10 5 cells per well in six-well gelatin-coated plates) and received 1 ml of each retroviral supernatant (three factors, OCT4, SOX2, KLF4, and the fourth factor corresponding to the NANOG constructs or empty control vector). This procedure was repeated every 12 h for 2 days (total of 4 additions). The day after infection was completed, medium was replaced by DMEM/10% FBS, and kept for 3 more days. At day 5, cells were trypsinized and reseeded on feeder plates. At day 6, medium was changed to human ES cell medium (see above under 'Cell lines' section). Seventy percent of the medium was replaced daily with fresh medium until colonies were visible and stained for AP at day 28.
Reprogramming efficiency
For quantification of iPSC generation efficiency, the total number of iPSC colonies was counted after staining plates for AP activity (AB0300 Sigma Alkaline Phosphatase Blue Membrane Substrate Solution (Sigma-Aldrich, St Louis, MO, USA) or SCR004 AP Detection Kit Chemicon (Millipore, Billerica, MA, USA)) following the manufacturer's instructions.
